bluuebunny/crossref_metadata_2025_split huggingface dataset:
Veno‐occlusive Disease of the Liver After Chemotherapy for Rhabdomyosarcoma: Case Report With a Review of the Literature
Authors: Kanwar Vikramjit S. , Albuquerque Maria Luiza C. , Ribeiro Raul C. , Kauffman William M. , Furman Wayne L. 
Published: February 2007

AbstractWe describe the case of a 3‐year‐old girl who developed veno‐occlusive disease of the liver while receiving chemotherapy for parameningeal rhabdomyosarcoma. After suffering lethargy and oral mucosal bleeding for one day, the patient exhibited a sudden weight gain and refractoriness to platelet transfusions. Symptoms rapidly worsened with elevation of liver enzymes, bleeding diatheses, and respiratory failure. An ultrasound scan of the liver demonstrated reversed flow in the portal vein. Maximal supportive care, including tracheal intubation and mechanical ventilation, was required. The patient gradually recovered with no respiratory and minimal neurological sequelae. Veno‐occlusive disease of the liver should be considered in children receiving chemotherapy who develop weight gain, a sudden drop in platelet count and derangement of liver enzymes. Aggressive supportive measures should be instituted if necessary, as patients surviving the acute phase can expect to make a full recovery. © 1995 Wi1ey‐Liss, Inc.
Cardiac Failure and Dysrhythmias 6–19 Years After Anthracycline Therapy: A Series of 15 Patients
Authors: Steinherz Laurel J. , Steinherz Peter G. , Tan Charlotte 
Published: February 2007

AbstractThe clinical course of late symptomatic anthracycline cardiomyopathy, and resultant changes of cardiac function, were described in 15 patients. They represented a subset of 300 patients who had cardiac evaluations to identify the prevalence of late cardiotoxicity more than 4 years after anthracycline therapy in these patients. The clinical course and all available cardiac evaluations including electrocardiography, continuous taped electrocardiography, echocardiography, radionuclide cardiac angiography, cardiac catheterization, and endomyocardial biopsy, of the 15 patients were reviewed. The patients had received 285–870 (median 540) mg/M2 of daunorubicin and/or doxorubicin 6–19 (median 12) years prior to the onset of late symptoms. Seven patients also had 2,100–4,000 cGy mediastinal radiotherapy. Five patients had required treatment for cardiac symptoms at the end of chemotherapy but 10 patients had no cardiac problems anteceding their late decompensation. Fractional shortening on echocardiogram at late decompensation was 8–20% (median 17%) and radionuclide left ventricular ejection fraction was 8–59% (median 38%). All were treated with digitalis and diuretics and 13/15 with afterload reduction, with at least transient improvement of symptoms. They were followed for 1–9 (median 3) years after late decompensation. One died of uncontrollable cardiac failure. Another underwent successful cardiac transplantation. Conduction abnormalities and dysrhythmias were present in 14/15 patients and 3 died suddenly. Two more had syncope, one requiring an automatic cardiac defibrillator. Endomyocardial biopsy or autopsy revealed hypertrophy and fibrosis in 10/10 patients. Our patients with early cardiac symptoms improved transiently but decompensated later and patients with no early symptoms developed cardiac symptoms more than 10 years after anthracycline therapy. Therefore, patients who have received anthracyclines should have continued cardiac evaluation. © 1995 Wi1ey‐Liss, Inc.
Safety and Efficacy of I‐Leucovorin Rescue Following High‐Dose Methotrexate for Osteosarcoma
Authors: Goorin Allen , Strother Douglas , Poplack David , Letvak Laurie A. , George Martine , Link Michael 
Published: February 2007

AbstractHigh‐dose methotrexate with leucovorin rescue (HDMTX‐LCV) is an important component of regimens used in the treatment of osteosarcoma. As of this writing the commercially available form of leucovorin is a racemic mixture of d‐ and l‐diastereoisomers; the l‐isomer is the active component. This study describes the efficacy and safety of l‐leucovorin in HDMTX‐LCV regimens. Fifteen patients with osteosarcoma who were enrolled into or treated according to Pediatric Oncology Group protocols 8759 and 8651 received l‐leucovorin (7.5 mg every 6 hours) in place of d,l‐leucovorin following high‐dose methotrexate. Safety data were collected for 1 week after each course or until any toxicities resolved. The mean number of l‐leucovorin doses per course was 16.2 and the mean total dose per course was 126 mg. Adverse experiences were generally mild or moderate and occurred in 54 (60%) of 90 courses of l‐leucovorin therapy. One l‐leucovorin patient, who had inadequate methotrexate rescue, developed severe typhlitis. There were no instances of severe, acute methotrexate toxicity. Myelosuppression was seen but, in general, was not severe. These results support the conclusion that l‐leucovorin effectively rescues patients from the toxicity of high‐dose methotrexate. © 1995 Wi1ey‐Liss, Inc.
Malignant histiocytosis: A reassessment of cases formerly classified as histiocytic neoplasms and review of the literature
Authors: Egeler R. Maarten , Schmitz Laura , Sonneveld Pieter , Mannival Carlos , Nesbit Mark E. 
Published: February 2007

AbstractMalignant histiocytosis (MH) and true histiocytic lymphoma (THL) are hematopoietic malignancies of the mononuclear phagocytic system distinguished from each other by clinical presentation and presumed cell of origin. THL present as a localized mass derived from the fixed tissue histiocyte which may or may not disseminate. MH originates from the circulating monocyte or tissue macrophage and is characterized by a syndrome of systemic symptoms, pancytopenia, adenopathy, hepatosplenomegaly, and wasting. The distinction between MH and THL is at times arbitrary and overlap exists between these syndromes. The clinicopathologic studies that defined these entities were performed prior to the development of immunophenotyping and other molecular techniques currently used to ensure proper classification of hematopoietic malignancies. Nine patients from the University of Minnesota originally diagnosed with MH were retrospectively analyzed using a panel of antibodies reactive against T cell, B cell, and myelomonocytic antigens. Only one patient was reclassified as a possible histiocytic malignancy after reevaluation. Similar immunophenotyping studies have also shown cases previously diagnosed as MH or THL express lymphoid antigens, and would now be classified as Ki‐1 positive anaplastic large cell lymphoma (ALCL) or some other hematopoietic neoplasm. These results indicate true histiocytic neoplasms are extremely rare, and previous concepts concerning clinical presentation and therapeutic outcome of the entities are inaccurate. In this paper we summarize the results of multiple retrospective analyses of cases previously diagnosed as MH or THL, including our experience at University of Minnesota, to illustrate the overall rarity of these entities. The current literature on malignant histiocytic disorders is reviewed, and the clinical presentation of patients determined to have histiocytic malignancies using contemporary analytical techniques is discussed. © 1995 Wiley‐Liss, Inc.
Cyclosporine therapy for refractory langerhans cell histiocytosis
Authors: Aricò Maurizio , Colella Roberto , Conter Valentino , Indolfi Paolo , Pession Andrea , Santoro Nico , Burgio G. Roberto 
Published: February 2007

AbstractOptimal treatment for Langerhans Cell Histiocytosis (LCH) has not yet been established. Preliminary reports suggest some effect of cyclosporine (CSA), both alone or in combination with steroids and/or vinblastine, in untreated cases. Twelve children (6 females and 6 males, age at diagnosis 3 months to 4 years) with biopsy proven, systemic LCH received oral CSA (12 mg/kg/day in two divided doses given daily) as a second‐line therapy following chemotherapy including vinblastine and/or etoposide (10 cases) or steroid alone (one case); one child was not pretreated. A total of 16 CSA courses were administered to the 12 patients: 8 were completed, 4 were interrupted as unsuccessful, and 4 are still ongoing. CSA related toxicity consisted of hypertrichosis and transient hypertension and was never limiting. Treatment was associated with a clinical response in 8/12 patients: 3 had a complete response and are off therapy, and 5 had a partial response; disease reactivation following first favorable response required additional CSA courses in 3 patients. Four patients failed to respond to CSA: two died of progressive disease, while two had a favorable response to CSA + VP16. Favorable response to CSA was not related to CSA trough and peak levels and was usually observed during the first 2 weeks of CSA therapy.CSA is effective for treatment of LCH also in pretreated children with progressive disease including life‐threatening organ dysfunction. Long‐lasting complete remission may be achieved after 6 to 12 months of CSA therapy. When disease reactivation occurs after treatment withdrawal, a second course may be followed by favorable response. As minimal or no adverse effects are observed during or after prolonged CSA therapy, this may also be safely used in young patients.
Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: Possible benefit of dexamethasone
Authors: van den Berg Henk , Vet Raymond , den Ouden Emmy , Behrendt Henk 
Published: February 2007

AbstractWe analyzed retrospectively the data on 135 children treated since 1983 for acute lymphoblastic leukaemia and non‐Hodgkin's lymphoma with bone marrow involvement with respect to the presence of lymphoblasts in cerebrospinal fluid (CSF) and the number of cells in CSF, both at initial diagnosis and during follow‐up. Of these children 96, 11, and 28 suffered from B‐progenitor, mature B‐cell, and T‐cell malignancies, respectively. In two patients initial central nervous system involvement was documented by the presence of lymphoblasts with high CSF cell counts (B+C+ patients); 19 patients had CSF lymphoblasts with normal CSF cell counts (B+C− patients); the others had no CSF blasts and normal CSF cell counts (B‐C‐ patients). In B+C− and B‐C‐ patients 5‐year‐leukaemia‐free survival was 66 and 70%, respectively (i.e., not significantly different). None of the B+C− patients experienced a first relapse in the central nervous system. Differences in outcome by comparing with reports of others may be related to the use of dexamethasone instead of prednisone in almost all of our patients. © 1995 Wiley‐Liss, Inc.
Anaplastic renal cell carcinoma following neuroblastoma
Authors: Krigman Hannah R. , Bentley Rex C. , Strickland Donald K. , Miller Cindy R. , Dehner Louis P. , Washington Kay 
Published: February 2007

AbstractRenal cell carcinoma is unusual in children. We report a case of anaplastic renal cell carcinoma arising in a 7‐year‐old girl following treatment for Stage III neuroblastoma. The renal cell carcinoma has unusual histologic and ultrastructural features, which are discussed. The case is further unusual in that few children with advanced stage neuroblastoma survive long enough to develop second malignant neoplasms. © 1995 Wiley‐Liss, Inc.
Transient myeloproliferative disorder associated with trisomy 21, a wide range syndrome: Report of two cases with trisomy 21 mosaicism
Authors: Zubizarreta Pedro , Muriel Federico Sackmann , Barbieri María Angélica Fernández 
Published: February 2007

AbstractTransient myeloproliferative disorder (TMD) is an uncommon syndrome strongly associated with abnormalities of chromosome 21. Blast transient proliferation appears most frequently at neonatal age and usually resolves spontaneously in two or three months.Two patients, a girl and a boy, with neonatal onset of TMD are reported. They both presented trisomy 21 mosaicism according to bone marrow cytogenetic analysis. Patient 1, on one end of the spectrum, showed a “classic” benign course with rapid resolution and favorable outcome. Patient 2, on the other hand, had two blast outbursts both followed by spontaneous remissions. He failed to thrive and never reached a good general condition, dying at 5 months of age from a respiratory infectious complication. The necropsy showed generalized extramedullary hemopoiesis without evidence of bone marrow blast infiltration or myelofibrosis.TMD has some clinical and laboratory features that make it unique and distinguishable from true congenital leukemia with which it may be initially mistaken. It usually has a benign course followed by a favorable outcome.As trisomy 21 mosaicism may not have overt phenotypic stigmata, it is possible that many cases of TMD in these children may have a silent, non‐detected course.We also conclude that a favorable outcome is not always to be expected in TMD. © 1995 Wiley‐Liss, Inc.
Dental abnormalities in long‐term survivors of head and neck rhabdomyosarcoma
Authors: Kaste Sue C. , Hopkins Kenneth P. , Bowman Laura C. 
Published: February 2007

AbstractTo define the long‐term dental sequelae of therapy for childhood rhabdomyosarcoma of the head and neck, and to identify factors in their development, we retrospectively reviewed the serial panoramic radiographs and clinical records of 22 survivors of head or neck rhabdomyosarcoma who had been followed for at least 5 years. Patients were divided into four groups based upon age at the time of therapy and three groups based upon radiation doses. All patients had received similar multiagent chemotherapy. Dental sequelae of oncotherapy occurred in over half of the long‐term survivors of head and neck rhabdomyosarcoma. The abnormalities comprised root stunting in 54%, microdontia in 23%, and hypodontia in 50% of patients; 36% had multiple abnormalities. Microdontia and multiple abnormalities were more prevalent in patients treated at the earliest age, and abnormalities tended to be more prevalent with increasing doses of radiation. Five patients (23%) developed severe cosmetic and/or functional sequelae necessitating surgical and/or orthodontic intervention. The high frequency of dental sequelae we observed suggests that meticulous long‐term dental and radiographic follow‐up are needed. Early detection and treatment of the complications of therapy will expedite their correction and minimize morbidity. © 1995 Wiley‐Liss, Inc.
Acquired von willebrand disease in malignant peripheral neuroectodermal tumor (PNET)
Authors: Nowak‐Göttl U. , Kehrel B. , Budde U. , Hoffmann C. , Winkelmann W. , Jürgens H. 
Published: February 2007

AbstractIn week 12 of the EICESS 92 protocol a 12‐year‐old boy with pelvic PNET developed acquired von Willebrand disease: bleeding time was prolonged (<15 min) and von Willebrand factor antigen (54%) and ristocetin cofactor activity (50) were reduced. Platelet aggregations with thrombin and collagen and the number of major platelet glycoproteins/per platelet did not differ from the controls. After Haemate P® (Behring Werke, Marburg, Germany) bleeding time normalized and surgery could be performed without occurrence of bleeding episodes. Three weeks after surgery bleeding time, ristocetin cofactor activity, and von Willebrand factor antigen increased to normal paediatric values. Without occurrence of further bleeding episodes the patient received another 10 courses of polychemotherapy (EICESS 92).
Acute limb ischemia due to malignant arterial embolism from a metastatic germ cell tumor
Authors: Stein Moshe E. , Drumea Keren , Ben‐Itshak Ofer , Hoffman Aharon , Eyal Abraham , Moshkovitz Boaz , Haim Nissim 
Published: February 2007

AbstractArterial tumor embolization is a rare but serious complication of neoplastic disease. The majority of these tumors are associated with primary or secondary lung malignancies, originating from pulmonary vein metastasis or from an atrial mass. Malignant germ cell tumors primarily disseminate to the retroperitoneal lymph nodes and lung, and to the brain and liver later in the course of the disease. A germ cell tumor metastasis embolizing to the iliac‐femoral arterial system has not yet been reported. We report a metastatic embolism in a patient with disseminated embryonal cell carcinoma causing acute limb ischemia, managed by surgical embolectomy. The sudden development of limb ischemia in a patient with a germ cell tumor should alert the physician to the possibility of tumor embolism. © 1995 Wiley‐Liss, Inc.
Childhood acute lymphoblastic leukemia in India: An approach to managementin a three‐tier society
Authors: Chandy Mammen 
Published: February 2007

AbstractWithin a population of 882 million, six thousand children will develop acute lymphoblastic leukemia each year in India. These children come from three socio‐economic backgrounds: Profile I (70%) being extremely poor who cannot afford any treatment unless it is provided free, Profile II (25%) from the middle class, and Profile III (5%) who can afford to have the best possible treatment. Current protocols for childhood ALL range from simple low‐cost regimes like UKALL VIII, intermediate intensity regimes like BFM 76/79, and aggressive regimes aimed at increasing cure rates in the high risk groups. Since state resources are limited, the pediatric oncologist in India has to decide on the appropriate treatment protocol for the individual child in each of these profiles. This paper suggests an approach to managing childhood ALL in developing countries like India. © 1995 Wiley‐Liss, Inc.
Hodgkin's disease in children: A retrospective study of the 20‐year experience (1968–1987) at a single institute
Authors: Kolygin Boris A. 
Published: February 2007

AbstractBetween 1968 and 1987, 356 previously untreated consecutive children with Hodgkin's disease (HD), aged under 14, were treated at the Pediatric Department of N.N. Petrov Research Institute of Oncology (St. Petersburg, Russia). Prevailing among histologic subtypes were lymphocytic predominance and mixed cellularity (34 and 31.7%, respectively). Two‐thirds of the patients (67.7%) were with Stages III‐IV and one‐third (32.3%) with Stages I‐II.Radiation therapy (RT) as a primary method of treatment was used in 72 patients (20.2%), chemotherapy (CT) in 76 (21.4%), and combined (RT + CT) therapy (CMT) in 208 cases (58.4%). The patients were followed from 6.3 to 26 years (median follow‐up was 13.7 years). For the whole group 5‐, 10‐, 15‐, 20‐, and 25‐year actuarial survival (S) rates were 90, 80, 74, 73, and 73%, respectively. The corresponding event‐free survival (EFS) rates were 63, 56, 56, 55, and 55%. The amelioration of the results was noted beginning with the 1973–1977 period, and for those treated in the last period (1983–1987) 5‐year S and EFS rates were 93 and 68%, respectively.We conclude, that the modern treatment is also effective for our children suffering from HD. © 1995 Wiley‐Liss, Inc.
Prostatic non‐Hodgkin's lymphoma causing acute urinary retention in childhood
Authors: Li Chi‐Kong , Yeung Chung‐Kwong , Chow John , Shing Matthew , Chik Ki‐Wai , Liu Kelvin , Yuen Patrick 
Published: February 2007

AbstractAn 8‐year‐old boy presented with dysuria and acute retention of urine. Rectal examination showed a hard mass arising from the prostate. CT scan of the pelvis confirmed the presence of a large prostatic tumor causing bladder outflow obstruction. A provisional diagnosis of pelvic sarcoma was initially made. Biopsy of the tumor mass however, revealed non‐Hodgkin's lymphoma of T‐cell type. The tumor showed very good response to chemotherapy and the urinary obstruction significantly improved with a week after starting therapy. © 1995 Wiley‐Liss, Inc.
B‐cell non‐Hodgkin's lymphoma presenting as a primary renal tumour in a child
Authors: Vujanić Gordan M. , Webb David , Kelsey Anna 
Published: February 2007

AbstractA 6‐year‐old boy presented with a unilateral renal tumour thought to be a Wilms' tumour. He had started a treatment but review of the histology and immunohistochemical studies proved the tumour to be a primary renal B‐cell lymphoma. This case illustrates the importance of an open‐minded approach in the histological examination of small round cell tumours in the kidney and immunohistochemical studies in such cases are strongly advocated. © 1995 Wiley‐Liss, Inc.
High‐dose‐rate brachytherapy in childhood sarcomas: A local control strategy preserving bone growth and function
Authors: Nag Subir , Olson Thomas , Ruymann Frederick , Teich Steven , Pieters Richard 
Published: February 2007

AbstractThe administration of external beam radiation therapy (EBRT) has been an integral part of the successful treatment of childhood sarcomas. However, EBRT has severe late morbidity in the developing child. In an attempt to deliver adequate tumoricidal radiation while preserving bone growth and organ function, 13 children with diverse sarcomas were treated with high dose rate brachytherapy (HDR). Seven patients had rhabdomyosarcoma and six patients had other soft tissue sarcoma variants. All patients were treated with disease‐appropriate chemotherapy, usually according to the Intergroup Rhabdomyosarcoma Study. Eleven patients received fractionated 36 Gy HDR alone at a mean of 3.5 months from diagnosis. Two patients received 10–12.5 Gy intraoperative HDR brachytherapy and additional 27 Gy EBRT. Nine of 11 patients in first remission have had no recurrences. One died of recurrent pulmonary metastases. The other patient that did recur is disease‐free 21 months post‐recurrence. Two additional patients were treated with HDR after tumor recurrence. One patient with recurrent Ewing's sarcoma, relapsed and died. The second is disease free 3 months after autologous bone marrow transplant. Grade 1 morbidity occurred in 46%, Grade 2 in 15%, and Grade 3 in 8% of the children, while relatively good bone and organ growth was maintained. The combination of conservative surgery, chemotherapy, and HDR offers the potential for disease control in young children while preserving bone growth and organ function. © 1995 Wiley‐Liss, Inc.
Simultaneous choriocarcinoma in mother and newborn infant
Authors: Picton Susan V. , Bose‐Haider Bratati , Lendon Mehroo , Hancock Barry W. , Campbell Richard H. A. 
Published: February 2007

AbstractA male infant, born following an uncomplicated pregnancy, was severely anaemic at birth following significant foeto‐maternal haemorrhage. At three weeks of age a tumour was found in the liver with evidence of metastatic disease in the lungs. The infant died before treatment could be started. Postmortem revealed choriocarcinoma which led to subsequent diagnosis in the mother who also had pulmonary metastases. The mother has been successfully treated. The case is described in detail and followed by a discussion and a literature review of reported cases of simultaneous choriocarcinoma in infant and mother. © 1995 Wiley‐Liss, Inc.